Another complement inhibitor therapy for myasthenia gravis: Is it NIMBLE enough?

The phase 3 NIMBLE trial demonstrated the efficacy of cemdisiran, an siRNA inhibitor of hepatic C5 synthesis, in patients with myasthenia gravis, making it the first complement inhibitor in the disease to employ this novel mechanism of action. These results expand the growing therapeutic landscape that already includes three FDA-approved complement inhibitors for myasthenia gravis.